| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 01/06/2010 | EP2140876A1 Therapeutic agent comprising vasohibin |
| 01/06/2010 | EP2139994A2 2786, a human aminopeptidase |
| 01/06/2010 | EP2139474A2 Transcription factor modulating compounds and methods of use thereof |
| 01/06/2010 | EP2139465A1 Composition comprising s-allylmercapto-n-acetylcysteine (assnac) for up-regulation of cellular glutathione level |
| 01/06/2010 | EP1513831B1 Novel compounds, their use and preparation |
| 01/06/2010 | EP1461073B1 Peptide agonists of prostate-specific antigen, and uses therefor |
| 01/06/2010 | CN100577651C Lactam compound and medicinal use thereof |
| 01/06/2010 | CN100577206C Controlled release composition and method of producing the same |
| 01/06/2010 | CN100577167C Use of pyridazino[4,5-b]indole-1-acetamide derivatives for preparing medicines for treating disease related to dysfunction of peripheral benzodiazepin receptors |
| 01/05/2010 | US7642903 Trailer tire alert system |
| 01/05/2010 | US7641922 Preparation and application of transhintotalphenolic acid |
| 01/05/2010 | US7641901 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 01/05/2010 | CA2426457C Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 01/05/2010 | CA2318192C .beta.2-adrenergic receptor agonists |
| 12/31/2009 | US20090326063 Synthetic triterpenoids and methods of use in the treatment of disease |
| 12/31/2009 | US20090326038 Method for treating a immunology-related disease |
| 12/31/2009 | US20090326026 Tricyclic Compounds Useful as Angiotensin II Agonists |
| 12/31/2009 | US20090325982 Phosphodiesterase 4 inhibitors |
| 12/31/2009 | US20090325289 Process for the multiplication of stem cells |
| 12/31/2009 | US20090324607 Therapeutic Transplantation Using Developing, Human or Porcine, Renal or Hepatic, Grafts |
| 12/31/2009 | US20090324599 activates FGF receptors, regulates the growth and differentiation of cells within the liver, regulates other cell types following secretion from the liver, plays a role in liver chemotaxis, has an oncogenic activity, or serves as an antigen for generating antibodies; treating diabetes or obesity |
| 12/30/2009 | WO2009158487A2 Treatment of nephrolithiasis and urolithiasis using 1,2,3,4,6-penta-o-galloyl-beta-d-glucose (pgg) |
| 12/30/2009 | WO2009157399A1 Sulfonamide compound or salt thereof |
| 12/30/2009 | WO2009120803A3 Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator |
| 12/30/2009 | WO2009111277A9 Imidazo [4. 5-b] pyridine derivatives used as raf inhibitors |
| 12/30/2009 | EP2138497A1 Novel adenine compound |
| 12/30/2009 | EP2138184A1 Prophylactic agent for renal failure |
| 12/30/2009 | EP2138175A2 Formulations comprising valsartan for treating diabetes or microalbuminuria |
| 12/30/2009 | EP2137213A1 Methods and compositions for treating prostate cancer |
| 12/30/2009 | EP2136818A1 Use of oligotide for the treatment of renal diseases |
| 12/30/2009 | EP2049525B1 N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof |
| 12/30/2009 | EP1523541B1 A process for decreasing environmental pollutants in an oil or a fat, a volatile environmental pollutants decreasing working fluid, a health supplement, and an animal feed product |
| 12/30/2009 | EP1487444B1 Use of pyridyl amides as inhibitors of angiogenesis |
| 12/30/2009 | CN201370888Y Multifunctional medicated pad |
| 12/30/2009 | CN101613321A Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
| 12/30/2009 | CN100574798C Method for preparing medicine for treating chronic renal insufficiency |
| 12/30/2009 | CN100574767C Composition for preventing mammmal vagina infection and use |
| 12/30/2009 | CN100574765C A medicine for treating hyperphosphatemia disease and iron deficiency anemia disease |
| 12/30/2009 | CA2728511A1 Sulfonamide compounds or salts thereof |
| 12/29/2009 | US7638551 Amino alcohol compounds or phosphonic acid derivatives thereof |
| 12/29/2009 | US7638546 Imidazolyl derivatives |
| 12/29/2009 | US7638528 Drug delivery agent containing an anticarcinogenic agent such as mitoxanthrone, doxorubicin, methotrexate etc. covalently linked to a compound via an ester, amido or carabamte linkage to the S, O or amino group of the compound |
| 12/29/2009 | US7638327 polypeptides related to a receptor to BAFF (a B-cell activating factor belonging to the Tumor Necrosis Factor family, which is associated with expression of B-cells and immunoglobulins); treatment of cancers, lymphomas, autoimmune diseases related to B-cells |
| 12/29/2009 | US7638141 Generating multipotent cells from sstem cells isolated from residual cord blood; tissue engineering and regenerative medicine |
| 12/29/2009 | CA2465877C Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase |
| 12/29/2009 | CA2443019C Kappa-opiate agonists for the treatment of bladder diseases |
| 12/29/2009 | CA2428133C Indolylmaleimide derivatives as protein kinase c inhibitors |
| 12/29/2009 | CA2415683C Indoloquinazolinones |
| 12/29/2009 | CA2387013C 6-position substituted indolinones, the preparation thereof and their use as pharmaceutical compositions |
| 12/29/2009 | CA2351488C Substituted 4-amino-2-arylcyclopenta[d]pyrimidines, their preparation, their use and pharmaceutical preparations comprising them |
| 12/24/2009 | US20090318522 comprising oxybutynin and pilocarpine; drug releasing pilocarpine between about 30 minutes to about 60 minutes after oxybutynin is released; treating overactive bladder; urogenital disorders |
| 12/24/2009 | US20090318452 INHIBITORS OF p38 |
| 12/24/2009 | US20090318429 Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives |
| 12/24/2009 | US20090318412 Tricyclic heterocyclic compound and use thereof |
| 12/24/2009 | US20090318365 Metastin derivatives and use thereof |
| 12/23/2009 | WO2009155448A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 12/23/2009 | WO2009155439A2 Use of nitrated lipids for treatment of side effects of toxic medical therapies |
| 12/23/2009 | WO2009154230A1 Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis |
| 12/23/2009 | WO2009153649A1 Process for preparing 3-substituted pyrrolidine compounds |
| 12/23/2009 | WO2009111739A3 Treatment of herpes virus related diseases |
| 12/23/2009 | WO2009111529A3 Method of treating polycystic kidney disease |
| 12/23/2009 | EP1549651B1 Pyrimidopyrimidones as kinase inhibitors |
| 12/23/2009 | CN101610779A 5ht4受体拮抗药 5ht4 receptor antagonist |
| 12/23/2009 | CN101608155A Kidney-invigorating health-care wine |
| 12/23/2009 | CN101607931A Preparation method of calcitriol |
| 12/23/2009 | CN101607076A Traditional Chinese medicine for treating uraemia |
| 12/23/2009 | CN101607060A Traditional Chinese medicine for treating urination incontinence |
| 12/23/2009 | CN101607058A Application of Chinese medicinal composition in preparing medicament for treating chronic nephritis |
| 12/23/2009 | CN101607026A New six-ingredient rehmannia pill |
| 12/23/2009 | CN101607025A Drug for curing and preventing cardiorenal failure and preparation method thereof |
| 12/23/2009 | CN101606987A Chinese veterinary medicament for preventing and treating animal viral disease |
| 12/23/2009 | CN101606971A Preparation method of Baikal skullcap root extract of bulk drug for livestock |
| 12/23/2009 | CN101606967A Chinese medicinal composition for treating diseases of urinary system |
| 12/23/2009 | CN101606952A Application of bifidobacterium lactis in preventing urinary system stones |
| 12/23/2009 | CN101606693A Natural colour lipid-lowering and weight-losing porridge and preparation method |
| 12/23/2009 | CN100571723C Chinese medicine composition for treating urinary infection |
| 12/23/2009 | CN100571695C Bilayer pharmaceutical tablets comprising telmisartan and diuretic and their preparation |
| 12/23/2009 | CA2725770A1 Plant-based compositions and uses |
| 12/22/2009 | US7635677 polypeptides related to a receptor to BAFF (a B-cell activating factor belonging to the Tumor Necrosis Factor family, which is associated with theexpression of B-cells and immunoglobulins); this receptor can be employed in the treatment of cancers, lymphomas, autoimmune diseases related to B-cells |
| 12/22/2009 | CA2416527C Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 12/22/2009 | CA2414514C Carbamates derived from arylalkylamines |
| 12/22/2009 | CA2387973C Pharmaceutical formulation containing tolterodine and its use |
| 12/22/2009 | CA2347752C N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them |
| 12/22/2009 | CA2173839C Transferrin compositions to alleviate the side effects of cytotoxic drugs |
| 12/17/2009 | WO2009152084A2 Adipose tissue-derived stem cells for veterinary use |
| 12/17/2009 | WO2009152070A2 Intradialytic administration of sodium thiosulfate |
| 12/17/2009 | WO2009151613A1 Oxybutynin derivatives |
| 12/17/2009 | WO2009151035A1 Therapeutic agent for overactive bladder |
| 12/17/2009 | WO2009150635A1 Treatment of chronic prostatitis |
| 12/17/2009 | WO2009150623A1 Treatment of chronic prostatitis |
| 12/17/2009 | WO2008117229A4 Muscarinic receptor antagonists |
| 12/17/2009 | WO2006006195A9 Antibacterial peptides and analogues thereof |
| 12/17/2009 | US20090312543 Pyrazole compounds useful as protein kinase inhibitors |
| 12/17/2009 | US20090312414 Treatment Of Lower Urinary Tract Dysfunction With CB2-Receptor-Selective Agonists |
| 12/17/2009 | US20090312412 3,4-diamino-3-cyclobutene-1,2-dione derivatives as potassium channel openers |
| 12/17/2009 | US20090312344 Arylpiperazine derivatives as adrenergic receptor antagonists |
| 12/17/2009 | US20090312328 Sulfonamide compound or salt thereof |
| 12/17/2009 | US20090312313 Compound having tgfbeta inhibitory activity and pharmaceutical composition comprising the same |
| 12/17/2009 | US20090311792 Fibroblast growth factor (FGF23) and methods for use |
| 12/17/2009 | CA2727852A1 Treatment of chronic prostatitis |